Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomanufacturing Changes: Trenches Littered With Lessons Learned

This article was originally published in The Gold Sheet

Executive Summary

A comparability template for biomanufacturing changes could serve as a model for biosimilars - but only if one can be established. As the dream of well-characterized biologics falters despite growing analytical prowess, industry and FDA are resigned to a case-by-case approach to comparability. Discussions at a recent DIA meeting focus on how to converge toward a common set of best practices, starting with a decision tree and testing hierarchy. The dominant role of bioequivalence PK studies in demonstrating biosimilarity is questioned. The difficulty of powering up animal studies sufficiently to detect subtle differences is discussed. Lessons learned are shared. Early and frequent discussion with FDA is encouraged to cut down on 'just in case' studies. Pending biosimilars legislation would set comparable 'highly similar' standards.

You may also be interested in...

A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study

The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.

Pandemic Will Continue Limiting US FDA Inspections In Driving FY 2021 Drug GMP Warnings

FDA historically has based 100% of drug adulteration warning letters on inspections but COVID-19-related travel restrictions began changing that in FY 2020, when 2% of drug GMP warning letters were based on testing import samples. The change became even more pronounced in the first two months of FY 2021, with 59% of actions related to sample testing and 41% to inspections.

Operation Warp Speed Angles For Greater Role In Pfizer COVID-19 Vaccine Manufacturing

Government offers help securing supplies in return for another 100 million doses by Q2. That would mean abandoning Pfizer’s preferred arms-length relationship.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts